Any feedback you have is welcome.
IMPRESSION:
1. Fluciclovine PET/CT with no definite signs of local or distant prostate cancer recurrence.
2. Focal uptake in the right sacrum, with no underlying bony changes, is indeterminate however likely secondary to degenerative change, attention on follow-up images is recommended. If clinically indicated, additional dedicated MRI might prove reasonable.
Background data:
Diagnosed with Gleason 7 (3+4) in July 2018. Radical prostatectomy in October 2018. PSA rising to .38 on August 12 2020. Decipher post RP test score was .37 (low risk). Determining next steps. I am located in Wisconsin. I had my robotic prostatectomy perfomed by Dr. Kenneth Jacobsohn at Froedtert near Milwaukee. I am looking at the University of Wisconsin Madison Dr. David Jarrard as the urologist/oncologist. Next steps as of Aug 19, 2020 is to pursue a scan (preferrably PSMA).
•Prostatic adenocarcinoma, Gleason 3+4 (score =7, Grade Group 2; 15% is pattern 4, not cribriform), bilateral and multifocal, within 2% of gland
•Tumor forms a dominant nodule in the left posterior peripheral zone (levels 8--11) measuring up to 10 mm (at level 8 or 9); also present in the right posterior levels 2—6
•Negative for extraprostatic extension (Stage pT2) - Organ confined
•Resection margins negative for tumor
•Seminal vesicles and vasa deferentia negative for tumor
•All not identified - Intraductal Carcinoma (IDC), xtraprostatic Extension (EPE), Urinary Bladder Neck Invasion, Seminal Vesicle Invasion, Lymphovascular Invasion, Perineural Invasion, Treatment Effect.
•Margins: Uninvolved by invasive carcinoma
•Regional Lymph Nodes: No lymph nodes submitted or found
•Pathologic Stage Classification (pTNM, AJCC 8th Edition)
•Regional Lymph Nodes (pN): pNX